Abstract
Immunization with plasmid DNA vectors represents a promising new approach to vaccination. It has been shown to elicit humoral and cellular immunity and protection in various infection models. Here, we assessed the immunogenicity and protective efficacy of a DNA vaccine vector encoding the antigen 85A (Ag85A) of Mycobacterium tuberculosis. Since intramuscular (i.m.) immunization with naked DNA requires considerable amounts of DNA in order to be effective, we evaluated a strategy to reduce the amount of DNA needed. To this end, we used Ag85A DNA adsorbed onto cationic poly(DL-lactide-co-glycolide) (PLG) microparticles and observed similar levels of protection against aerosol challenge in mice using doses of PLG-DNA two orders of magnitude lower than with naked DNA itself.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adsorption
-
Animals
-
DNA Primers
-
Drug Delivery Systems
-
Injections, Intramuscular
-
Interferon-gamma / metabolism
-
Lactic Acid
-
Mice
-
Mice, Inbred BALB C
-
Microspheres
-
Mycobacterium bovis / genetics
-
Mycobacterium bovis / immunology
-
Mycobacterium tuberculosis / genetics
-
Mycobacterium tuberculosis / immunology
-
Polyglycolic Acid
-
Polylactic Acid-Polyglycolic Acid Copolymer
-
Polymers
-
Reverse Transcriptase Polymerase Chain Reaction
-
Spleen / cytology
-
Spleen / metabolism
-
Spleen / microbiology
-
T-Lymphocytes / metabolism
-
Tuberculosis / immunology
-
Tuberculosis / microbiology
-
Tuberculosis / prevention & control*
-
Tuberculosis Vaccines / administration & dosage*
-
Tuberculosis Vaccines / chemistry
-
Tuberculosis Vaccines / therapeutic use*
-
Vaccines, DNA / administration & dosage
-
Vaccines, DNA / chemistry
-
Vaccines, DNA / therapeutic use
Substances
-
DNA Primers
-
Polymers
-
Tuberculosis Vaccines
-
Vaccines, DNA
-
Polylactic Acid-Polyglycolic Acid Copolymer
-
Polyglycolic Acid
-
Lactic Acid
-
Interferon-gamma